Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
Price : $35 *
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms DAFNE
- Sponsors Astellas Pharma
- 11 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.